Home » Stocks » ALVR

AlloVir, Inc. (ALVR)

Stock Price: $38.95 USD -2.96 (-7.06%)
Updated Jan 26, 2021 3:56 PM EST - Market open
Market Cap 2.63B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 40.47M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $38.95
Previous Close $41.91
Change ($) -2.96
Change (%) -7.06%
Day's Open 42.04
Day's Range 37.55 - 42.04
Day's Volume 273,457
52-Week Range 21.05 - 46.81

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 day ago

The US IPO market is expected to remain active in the week ahead with eight IPOs slated to raise $4.6 billion. Street research is expected for Medirom Healthcare Technologies on Monday, 1/25.

Other stocks mentioned: ABST, AGFY, FTHM, GOED, LI, MRM, SAP, VERX, VITL, VSTA, XM
Business Wire - 2 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one po...

Business Wire - 3 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Mo...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that the U.S. Food and Drug Administration (FDA) has cleared t...

Business Wire - 1 month ago

--(BUSINESS WIRE)--AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely we...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that results from the Phase 2, proof-of-concept CHARMS s...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that preclinical data presented in an oral presentation ...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthca...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations tha...

GlobeNewsWire - 3 months ago

Findings Demonstrate Significantly Higher Health Care Costs, Health Resource Utilization, and Worse Clinical Outcomes Among Allo-HCT Patients with Viral Infections Findings Demonstrate Signifi...

GlobeNewsWire - 4 months ago

- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients

GlobeNewsWire - 4 months ago

Appointment Expands AlloVir’s Regulatory Expertise as Company Plans to Initiate Multiple Pivotal and Proof-of-Concept Trials Appointment Expands AlloVir’s Regulatory Expertise as Company Plans...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley ...

Benzinga - 5 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Other stocks mentioned: XRX, CODI, EHTH, FFIV, IQV, QDEL
GuruFocus - 5 months ago

Stock of virus therapy biotech up more than 70% in just a few days

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the closing of its upsized initial public offeri...

Market Watch - 5 months ago

AlloVir Inc. said Thursday that its upsized initial public offering priced at $17 a share, in the middle of the expected range of $16 to $18 a share.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of its upsized initial public offeri...

About ALVR

Allovir, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human me... [Read more...]

Industry
Biotechnology
IPO Date
Jul 30, 2020
CEO
David L. Hallal
Employees
32
Stock Exchange
NASDAQ
Ticker Symbol
ALVR
Full Company Profile

Financial Performance

In 2019, AlloVir's revenue was $165,000, a decrease of -85.46% compared to the previous year's $1.14 million. Losses were -$23.84 million, 881.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for AlloVir stock is "Buy." The 12-month stock price forecast is 46.50, which is an increase of 19.38% from the latest price.

Price Target
$46.50
(19.38% upside)
Analyst Consensus: Buy